part of Epigenomics
Review 2016/01/30 8
2
2016
In response to environmental cues, enzymes that influence the functions of proteins, through reversible post-translational modifications supervise the coordination of cell behavior like orchestral conductors. Class IIa histone deacetylases (HDACs) belong to this category. Even though in vertebrates these deacetylases have discarded the core enzymatic activity, class IIa HDACs can assemble into multiprotein complexes devoted to transcriptional reprogramming, including but not limited to epigenetic changes. Class IIa HDACs are subjected to variegated and interconnected layers of regulation, which reflect the wide range of biological responses under the scrutiny of this gene family. Here, we discuss about the key mechanisms that fine tune class IIa HDACs activities.
First draft submitted: 8 September 2015; Accepted for publication: 29 October 2015; Published online: 21 January 2016
Keywords: AMPK • FOXO • HDAC4 • HDAC5 • HDAC7 • HDAC9 • LKB • MEF2 • PKD • SIK
The class IIa HDACs
Lysine acetylation is a post-translational modification (PTM) that, when exercised on histones, plays a key role in marking transcriptionally active genomic regions. Similarly to other PTMs, acetylation is not restricted to chromatin remodeling but it can modulate different molecular machineries, which control cell cycle progression, actin nucleation, splicing and nuclear transport [1].
Lysine-acetylation homeostasis is under the supervision of two families of enzymes, with antagonistic activities: the histone ace-tyl transferases and the histone deaceace-tylases (HDACs). HDACs repertoire in mammals comprises 18 genes that can be grouped into five subfamilies on the basis of their sequence homology and phylogenetic criteria [2]. To
the subclass IIa belong HDAC4, HDAC5, HDAC7 and HDAC9 (for an excellent review on HDACs see [2]). These proteins share
spe-cific and characteristic features, which are highlighted in Box 1.
Class IIa HDACs as part of multiprotein complexes are involved in the regulation of assorted cellular responses. They generally act at the apex of specific genetic programs, by influencing the landscape of gene expressed in a specific context. Although principally investi-gated as regulators of transcription and in par-ticular of myocyte enhancer factors (MEF2) transcription factors, alternative partners and functions, in particular when localized in the cytoplasm, cannot be excluded (for a discus-sion on some class IIa HDACs partners see [3]).
Similarly to other epigenetic modifiers, class IIa HDACs do not recognize the DNA, instead by interacting with a selected num-ber of transcription factors, they are recruited on specific genomic regions in a sequence-dependent manner [2]. During embryonic
development, class IIa HDACs are actively involved in controlling specific differentia-tion pathways and tissue morphogenesis. In adult tissue they are part of several adaptive responses (for recent reviews see [4,5]).
Regulation of class IIa HDAC activities: it is
not only matter of subcellular localization
Eros Di Giorgio1 & Claudio Brancolini*,1
Not surprisingly, these arenas of copious interven-tions find correspondence in the multiple opinterven-tions available to oversee class IIa HDACs activities. In this review, we will discuss about these different options and how cells and the microenvironment govern class IIa HDACs activities.
Transcription is the first decision: when & where
Paradoxically, although the tissue-specific expression of class IIa HDACs was immediately considered a dis-tinctive trait of this subfamily [4], a limited number of
studies have addressed the control operated at the level of transcription on these genes. Apparently, class IIa HDACs transcription is under the control of many signaling pathways.
Genomic organization
The complexity of such regulation is mirrored by the existence of several transcriptional variants. A sum-mary of the genomic organization of the different class IIa HDACs is shown in Table 1. Concerning HDAC4 only a single isoform has been described up to now, composed by 26 coding exons and 1 noncoding exon (mRNA 8980 bp and ORF/open reading frame, 3252 bp-long) [6]. The reference sequence of the longer
RNA encoded by HDAC5 locus is 5324 bp and pro-duces a 3369 bp ORF that comprises all coding exons of
its paralog HDAC4 [6]. A second described transcription
variant of HDAC5 lacks exons 14 and 15 and produces a protein of 75 amino acids (aa) shorter, characterized by a deficient catalytic domain [6]. Two different splicing
isoforms of HDAC7 have been characterized [6,7]: the
most common spliced isoform is made up of 25 exons and an unspliced isoform that retains the first intron after the first ATG [7]. This unspliced mRNA could in
principle produce two products. A small peptide of 7 aa and a protein of 22 aa shorter compared with the common form [7]. In this case a second ATG proficient
in translation is used [7]. The unspliced and spliced
isoforms differentially influence cell proliferation and their generation is regulated during vascular smooth muscle cells (VSMCs) differentiation [7,8]. Curiously,
the last 612 bp of HDAC7 are antisense respect to the SLC48A1 gene, raising the possibility of an involvement in controlling the translation of this gene [6].
The canonical isoform of HDAC9 is made up of 23 coding exons, which are translated into a 1011 aa polypeptide [6,9]. A well-known variant of HDAC9 is
called MITR or HDAC9ΔCD (HDRP/MITR) [10]. It
generates a shorter protein (593 aa) lacking the deacet-ylase domain. This variant is not a simple truncation of full-length HDAC9, because it retains 16 unique resi-dues codified by intron 12 which are 3′ to the canoni-cal splice donor site [9]. Despite the truncation, MITR
represses MEF2-dependent transcription [10].
Box 1. Class IIa histone deacetylases hallmarks.
• An extended amino-terminal region involved in the interaction with several partners and different transcription factors, which recruits these repressors on specific genomic regions
• A carboxy-terminal deacetylase domain that, in vertebrates, is enzymatically ‘inactive’ (or at least inactive vs acetyl-lysine)
• The co-presence of nuclear localization sequences and of nuclear export sequences, which confers environmental signaling regulated nuclear/cytoplasmic shuttling
• Interactions with several partners, comprising multiprotein complexes recruiting class I histone deacetylases, which confer the deacetylase activity
Table 1. Class IIa histone deacetylases genomic organization.
Histone deacetylases
Localization Extension TSSs SV mRNA Exons Longer ORF
HDAC4 Chr 2q37.3 minus strand 353479 7 16 s 6 uns 1 27 (26c/1nc) 3256 HDAC5 Chr 17q21 minus strand 46893 8 17 s 6 uns 2 27 (26c/1nc) 3369 HDAC7 Chr 12q13.1 minus strand 37890 17 31 s 5 uns 2 25 2856 HDAC9 Chr 7p21.1 plus strand 912579 9 17 s 6 uns 6 23 3033
Extension: Genomic bp; mRNA: Described mature mRNAs; ORF: Open reading frame; S: Spliced; SV: Different splicing variant; TSS: Different transcription start site; Uns: Unspliced.
Removal of exon 7 during splicing generates a protein (HDAC9Δexon7) which is 37 aa shorter and that lacks two serines (Ser223 and Ser253) involved in the nuclear export and a portion of the nuclear localization signal. Another exon that may be removed is the twelfth. The corresponding protein is 981 aa long and, since the exon 12 contains the SUMOylation site, this splice variant cannot be SUMOylated [9,11]. Additional HDAC9
splicing variants include an isoform lacking both the seventh and the twelfth exons [9] and a deletion of a
portion of the 15th exon, which generates similarly to MITR, a protein deprived of the deacetylase domain [9]. Transcriptional control
Experimentally, the expression of HDAC4 can be repressed by mithramycin [12], which after binding to
GC-rich sequences displaces the Sp transcription fac-tors [13]. Binding of Sp1 and Sp3 to the HDAC4 promoter
was confirmed by EMSA and ChIP experiments and the manipulation of Sp1 and Sp3 expression was coupled to a parallel variation of HDAC4 expression [12].
Further-more, the antineoplastic properties of the turmeric root derivative curcumin seem to partially depend on the inhibition of the Sp1 action on HDAC4 promoter [14].
Also HDAC7 transcription seems to be under the control of Sp1. In particular, it was reported that Sp1 stimulates the transcription of HDAC7 mRNAs dur-ing the PDGF-BB-induced differentiation of murine embryonic stem cells into smooth-muscle cells (SMCs) [15]. HDAC7 expression is similarly induced by
PDGF-BB also in VSMCs [16].
In addition to Sps, class IIa HDACs transcription must depend on additional circuits, operating in a tissue-specific manner. For example, HDAC4 expres-sion is induced after denervation in atrophic muscles, where it influences a metabolic shift [17]. A
feed-for-ward mechanism is involved in such regulation. The initial nuclear relocalization of HDAC4 in atrophic muscles causes the activation of myogenin, which in turn induces HDAC4 transcription, thus alimenting the expression of the deacetylase [17].
In bones, HDAC4 is the highest expressed class IIa HDACs and it plays an irreplaceable role in the process of chondrocyte hypertrophy [18]. During skeletogenesis,
the levels of HDAC4 increase in murine prehypertro-phic chondrocytes in the growth plate at E18.5, while HDAC4 is not expressed at detectable levels in pro-liferating chondrocytes, in bones and osteoblasts [18].
The contribution of the transcriptional machinery in this switch is unknown.
Similarly, HDAC7 is highly expressed in pre-B cells but dramatically downregulated, both at RNA and pro-tein levels, during lineage conversion to macrophages [19].
Although HDAC7 repression is necessary for the
tran-scription of MEF2-target genes, which are important for macrophage functions, the mechanisms that control HDAC7 levels still need to be investigated [19].
In embryonic stem cells Oct3/4 prevent HDAC4-mediated repression of stemness, by binding the first intron of the deacetylase and thus interfering with splicing maturation [20]. This regulation was
hypothe-sized to limit the negative influence of class IIa HDACs on stemness, possibly through the repression of Oct3/4 and Klf4 genes.
Upregulation of class IIa HDACs transcription is observed during muscle differentiation, as part of a negative-feedback loop, to fine tuning the rate of differ-entiation. In this case MEF2A, MEF2C and MEF2D are able to bind the promoter of Hdac9 and to induce its expression [21]. It is not clear at the moment whether
MEF2s regulate directly also the transcription of other class IIa HDACs (see below).
The control operated by MEF2s on class IIa tran-scription could also be involved in the compensatory responses observed in different experimental settings. In certain cell lineages when a class IIa HDAC mem-ber is depleted another memmem-ber is upregulated [22–24].
Once MEF2 get rid of a class IIa HDACs member, they might transcribe other members of the family, by binding to the proximal promoter (in case of HDAC5 and HDAC9) or to the enhancer (for HDAC4 and HDAC7; see below).
Although few information are available on the tran-scriptional control operated on class IIa HDACs, the ENCODE project disposes of the ChIP-Seq data for several transcription factors (TFs) and other elements controlling transcription [25]. Numerous elements
including TFs, epigenetic modifiers and architec-tural proteins bind the proximal promoter of HDAC4 and HDAC7, thus suggesting that transcription of these two deacetylases is under intense supervision (Figure 1). Less covered are the proximal promoters of HDAC5 and of HDAC9. Binding of MEF2 TFs was confirmed in the proximal promoter of HDAC9 (Figure 2). MEF2s bind also the HDAC5 proximal pro-moter, hence also this deacetylase can be under control of MEF2s as part of a negative feedback loop [24]. In
general, the complexity of TFs and epigenetic regula-tors assembling onto the promoters of class IIa HDACs testifies the importance of the transcriptional control in the homeostasis of this gene family.
Different proto-oncogenes and cell cycle supervisors bind the promoters of class IIa HDACs (Figures 1&2). Interestingly, in support of an involvement of HDAC4 and HDAC7 in the processes of oncogenic transfor-mation [26], some proto-oncogenes such as JUN, FOS,
Figure 1. Available ChIP-Seq data from eight different cells lines were analyzed for the binding to the proximal promoters (-1/-1000)
of HDAC4 and HDAC7. Transcription factors (red), epigenetic modifiers (green), basic transcriptional machinery (blue), architectural
proteins (violet) and their relative region of binding are indicated.
HDAC4 (NM_006037) promoter HDAC7 (NM_015401) promoter HA-E2F1 RAD21 CTCF ELF1 SIN3AK20 TFAP2A PoI2 (pS2) HA-E2F1 E2F6 MXI1 NRF1 E2F4 ATF3 USF1 MYC USF2 E2F6 ESRRA PAX5 ETS1 POU2F2 OCT2 MAX EGR1 SETDB1 NANOG REST TAF7 GATA-1 TBP PAX5 PoI2 SIN3AK20 TFAP2C THAP1 YY1 PoI2(pS2) CEBPB PoI2 SMC3 ESR1 USF1 PoI2 TAF1 NR3C1 GTF2F1 MYC MAX FOSL2 RFX5 JUND FOS FOS2L1 TFAP2C FOS EP300 JUN SP1 JUND TBP STAT3 EGR1 JUNB HDAC2 GATA-3 GATA-2 NR3C1 MAX FOXA2 FOXA1 FOXA1 PoI2 (pS2) MYC SMARCB1 CTCF ELF1 PoI2 ESR1 HEY1 E2F6 HDAC2 YY1 ETS1 HA-E2F1 PoI2 E2F1 E2F6 HMBN3 CCNT2 TBP TAL1 TAF1 GATA-3 GATA-2 PoI2 PoI2 HEY1 YY1 TAF1 NFKB ELF1 BHLHE40 GABP Pbx3 SP2 NF-YA c-Fos PoI2 NF-YB SP1 CDH2 NRF1 CEBPB IRF1 NF-YA STAT3 RFX5 SP2 NF-YB SP1 Pbx3 PoI2 TAF1 HEY1 STAT1 PoI2 -1200 -1000 -800 -600 -400 -200 -1200 -1000 -800 -600 -400 -200
proto-oncogenes could be responsible for the upreg-ulation of HDAC7 mRNA observed in response to PDGF or serum stimulation [15] and of HDAC4
dur-ing differentiation of osteoblasts exposed to EGF-like ligands [27]. The ENCODE project finds at least six
regulators, which bind the immediate early promoter of all the four class IIa HDACs: Pol2, TAF1, TBP, SP1, YY1, MAX. Not surprisingly, the first three belong to the basal transcription machinery. The presence in this list of Sp1 confirms the early studies above described. Regarding YY1, it usually binds the
chromatin in close proximity of the transcription start site of highly expressed genes [28]. The contemporary
presence of MAX and YY1 on the promoters of these deacetylases suggests that class IIa HDACs could be part of the Myc transcription network.
Control of the mRNA stability: miRNAs targeting class IIa HDACs in physiological contexts
targeting these enzymes were initially discovered by studying muscular and chondrocyte differentiation. During myogenesis MEF2, in addition to the nega-tive feedback loop involving HDAC9, controls also the expression of miR-1, which targets HDAC4 mRNA, thus fueling a positive feedback loop [29,30]. However,
this model is complicated by the fact that miR-1 can also target the 3´UTR of MEF2A [31]. A similar
posi-tive feedback loop is operaposi-tive during neurogenesis. In this case MEF2C promotes the transcription of miR-9, which targets the 3´UTR of HDAC4 [32].
In myoblasts the relative abundance of miR-1 and miR-133 contributes to the equilibrium between pro-liferation and terminal differentiation [29]. In
partic-ular, miR-1 targets the 3´UTR of HDAC4 and pro-motes myogenesis, while miR-133 destabilizes serum response factor and sustains proliferation. Curiously, the two miRNAs derive from the same polycistronic pre-miRNA and are transcribed together [29].
Impor-tantly, in embryonic hearth and in the somite, MEF2 together with MyoD positively regulate the tran-scription of both these miRNAs, by binding to an miR-1/-133 intragenic enhancer [30].
miR-1 is required for the correct fusion of myoblasts but it is also induced by the mTOR pathway and has prohypertrophic properties [33]. miR-1 stimulates also
chondrocyte hypertrophy again through HDAC4 inhibition [34]. Another miRNA upregulated during
chondrogenesis is miR-365. In particular, miR-365 is mechanosensitive and determines the induction of Hh and collagen X expression, the latter through the direct targeting of HDAC4 [35]. During osteoblast
differen-tiation, HDAC4 is also regulated by miR-29b, which promotes osteogenesis [36].
TGF-beta represses myogenesis and muscle differ-entiation. In C2C12 cells, TGF-beta inhibits muscle differentiation, through the repression of miR-206 and miR-29 and thereby by augmenting HDAC4 expres-sion [37]. Importantly, miR-206 represses hypertrophy
of myocytes in vitro but has no effects in the regulation of muscle hypertrophy in vivo, although in both cases it causes a massive drop in HDAC4 levels [37]. Among
the plethora of responses regulated by miR-206, it was described that the repression of HDAC4 delays amyotrophic lateral sclerosis progression and pro-motes regeneration of neuromuscular synapses [38,39].
Finally, miR-206 displays strong tumor-suppressive properties in gastric cancers, again partially due to the repression of HDAC4 [40]. Recently, a cross-talk
between the NRF2, HDAC4 and miR-1/miR-206 was described in cancer cells and in vivo tumor mod-els [41]. In KEAP-1-deficient lung cancer cells NRF2
is hyperactive and promotes the reduction of cyste-ines 667 and 669 in HDAC4 (see below). As a
conse-quence, HDAC4 accumulates in the nucleus [41,42] and
represses the transcription of miR-1 and miR-206 [41].
Among miR-1 and miR-206 targets there are key-genes involved in the control of pentose phosphate pathway and tricarboxylic acid cycle [41]. Therefore the
activa-tion of NRF2 in cancer cells, at least in part through the HDAC4-mediated repression of miR-1/miR-206, reprograms glucose metabolism toward the pentose phosphate pathway thus providing the substrates needed to support cell growth [41].
Another pathway controlling HDAC4 mRNA sta-bility, via the same miRNAs (MEF2/miR-1/miR-206/ NOTCH3) is active in myoblasts, where it ensures that differentiation takes place with the right timing [43,44].
NOTCH3 delays muscle differentiation at least in part by promoting the dephosphorylation of MEF2. An increase in MEF2 levels is sufficient to overcome this inhibition and to directly transcribe miR-1 and miR-206. In turn, these miRNAs have a double pro-differentiative effect since they target both HDAC4 [29]
and NOTCH3 [43].
Certain studies have proposed a role of HDAC4 in the pathogenesis of Huntington’s disease [45,46]. In
agreement, targeting of HDAC4 by miR-22 shows neuroprotective effects [47]. miR-22 is upregulated
also during myocyte differentiation and cardiomyo-cyte hypertrophy [47]. Its overexpression is sufficient
to induce cardiomyocyte hypertrophy in vivo, while miR-22-null hearts are resistant to stress-induced car-diac hypertrophy [48]. These phenotypes at least in part
might be explained by the suppression of HDAC4 [48].
miR-22-mediated silencing of HDAC4 is also involved in the pathogenesis of emphysema [49]. In
particular, high levels of miR-22 are present in antigen presenting cells, derived from a murine model of lung emphysema. This upregulation causes a strong decrease in HDAC4 levels and the subsequent increase in the release of IL-6. IL-6 stimulates the activation of the TH17 subset of helper T cells that are responsible for the establishment of a state of chronic inflammation [49].
Finally, some miRNAs regulated during embryo-genesis recognize HDAC4 mRNA, thus abolishing its repressive activities on certain loci. For example in the fetal brain, levels of the epigenetic regulators methyl CpG-binding protein 2 and HDAC4 are kept low by presence of miR-483-5p [50].
While in literature the stability of the 3´UTR of HDAC4 has been studied in details, little information are currently available on the regulation of the other class IIa HDACs by miRNAs. Few miRNAs target the 3´UTR of HDAC5 in an exclusive manner. One of them is miR-2861 [51,52]. Similarly and redundantly to
-1200 -1000 -800 -600 -400 -200 -1200 -1000 -800 -600 -400 -200 HDAC5 (NM_005474) promoter HDAC9 (NM_058176) promoter
CTCF PoI2 HEY1 PAX5 ZBTB7A CTCFL E2F6 ZNF143 SIN3AK20 CTCF TAF1 SMC3 RAD21 EBF CTC
F
CEBPB MYC HEY1 PoI2 (pS2)
MEF2C EGR1 MEF2A NFKB GATA-2 RAD2
1
YY1 MEF2A EP300 MEF2C PAX5 SP1 PAX5 MAX YY1 BCL11A TBP POU5F1 PoI2 TAF1 ZNF26
3
EP300
Figure 2. Available ChIP-Seq data from eight different cells lines were analyzed for the binding to the proximal
promoters (-1/-1000) of HDAC5 and HDAC9 (see facing page). Transcription factors (red), epigenetic modifiers
(green), basic transcriptional machinery (blue), architectural proteins (violet) and their relative region of binding are indicated.
the targeting of HDAC5 and the subsequent activation of RUNX2 [51]. miR-2861 also targets the 3´UTR of
HDAC5 in hamster ovary CHO cells [52]; by decreasing
HDAC5 levels, miR-2861 enhances the productivity of these cells that are frequently used as cell factories for the production of recombinant proteins, feeding the industrial and economic interest around this miRNA.
Very recent is the finding that HDAC9 dysregula-tion may be involved in the age-related bone loss [53]. In
particular, old mice are characterized by an increase of miR-188 levels in bone marrow stromal cells. miR-188 targets HDAC9 and RICTOR expression and the silenc-ing of these two genes seems to be sufficient to regulate the switch between osteogenesis and adipogenesis in bone marrow stromal cells [53].
Control of the mRNA stability: miRNAs targeting class IIa HDACs in cancer
Interestingly, most of the miRNAs that target the 3´UTR of class IIa HDACs are repressed in certain can-cers and display tumor suppressive traits. This observa-tion is in agreement with the reported oncogenic prop-erties of class IIa HDACs [23,26]. miR-1 is repressed in
several cancers, such as lung cancer [54],
hepatocellu-lar carcinoma (HCC) [55] and chordoma [56]. In these
contexts its repression is associated to the upregulation of FoxP1, MET and HDAC4 [54,55]. A similar
upreg-ulation of HDAC4 was correlated, in several HCC samples, with a reduced expression of miR-22 [57].
HDAC4 is targeted also by miR-140. In osteosarcoma and colon cancer cells this miRNA is associated with chemosensitivity [58].
Waldenström macroglobulinemia, a rare B cell low-grade lymphoma, is characterized by a reduced expres-sion of miR-9* [59]. This microRNA directly affects the
levels of HDAC4 and HDAC5. Restoring of miR-9* levels provokes the downregulation of class IIa HDACs and increases p21/CDKN1A levels [60,61], thus
limit-ing Waldenström macroglobulinemia cells prolifera-tion [59]. An autoregulatory loop, as above described
for miR-1, involves miR-200a and it is deregulated in HCC. miR-200a affects the stability of HDAC4 and, in a feedback manner, the deacetylase decreases miR-200a transcription, by disturbing the binding of Sp1 to its promoter. Downregulation of miR-200a enhances the proliferation and migration of HCC cells, whereas its upregulation inhibits both the responses [62].
Similar correlations between HDAC4, microRNAs and tumors have been observed in breast cancer, where low levels of miR-125a-5p are bad
prognos-tic markers and the majority of the tumor suppres-sive properties of miR-125a-5p depends on HDAC4 suppression [63].
In B cells, unlike the aforementioned cases, the upreg-ulation of a miRNA (miR-155) that targets HDAC4 has proliferative effects [64]. These differences could
reflect cell lineages specificities or the contribution of additional genes under the influence of miR-155.
In tongue squamous cell carcinoma, miR-140-5p can influence the expression of a gene cluster that includes ADAM10, LAMC1, PAX6 and HDAC7. These genes affect cell motility and could be responsible for the metastatic phenotype [65]. miR-34 can repress HDAC7
as well as HDAC1 expression. In breast cancer miR-34 is significantly downregulated, HDAC1 and HDAC7 levels are augmented and as a consequence HSP70 is deacetylated. The authors proposed that such modi-fication confers resistance to chemotherapy-induced autophagic cell death [66].
A summary of the different microRNAs targeting class IIa HDACs is reported in Table 2.
Proteolytic processing or massive degradation
Selective proteolysis can influence class IIa HDACs activities. During apoptosis, HDAC4 and HDAC7 are cleaved, respectively, by caspase-3 [67] and
cas-pase-8 [68]. In both cases the cleavage products increase
the apoptotic rate [67–69], but only for HDAC4 the
amino-terminus generated-fragment is competent for MEF2 repression [67].
Another selective proteolytic processing was observed to modulate the hypertrophic response. In cardiomyocytes, protein kinase A (PKA) activation causes the cleavage of HDAC4 between residues 201 and 202, operated by an unidentified protease [70]. The
generated amino-terminal fragment accumulates in the nucleus and it is competent for MEF2 repression but it is incompetent for SRF repression [70]. The binding
site for PKA is present only in HDAC4 (aa 638–651), among all class IIa HDACs. The anti-hypertrophic effect of PKA is sufficient to antagonize the pro-hypertrophic actions of CaMKII, without affecting cardiomyocyte survival [70].
The ubiquitin-proteasome system (UPS) can also affect class IIa HDACs levels. Treatment of HEK293 cells with ALLN and MG132, two inhibitors not entirely proteasome-specific, provokes an increase in the levels HDAC4, HDAC5 and HDAC7 [71].
HDAC7 is degraded mainly in the cytoplasm after its phosphorylation-mediated export from the nucleus [71].
The UPS degradation of HDAC7 in the cytoplasm was recently confirmed during endochondral ossifica-tion [72]. Class IIa HDACs are negative modulators of
endochondral ossification, at the stage of chondrocyte hypertrophy, by repressing the activity of RUNX2 and MEF2s [18,73]. HDAC7 is highly expressed in
prolif-erating cells within the growth plate and its postna-tal deletion increases the proliferation rate, because of β-catenin activation. During chondrocytes matura-tion, HDAC7 is exported into the cytoplasm where it is degraded by the UPS and liberates β-catenin [72].
The degradation of HDAC4 and HDAC5 was observed in vivo in muscles during fiber type conver-sion [74]. Contrary to HDAC7, the degradation of these
class IIa HDACs takes place in the nucleus [74]. Nuclear
degradation of class IIa HDACs was confirmed in untransformed cells exposed to serum starvation [75].
In this case GSK3β phosphorylates HDAC4 on serine 298 and this phosphorylation acts as a priming event required for its ubiquitylation and nuclear degradation (Figure 3 and Table 3)[75].
Degradation of class IIa HDACs as an environment driven process was observed also in a rat osteoblastic cell line. Here, the stimulation of differentiation with para-thyroid hormone (PTH) causes PKA-dependent phos-phorylation of HDAC4 on serine 740, its export in the cytoplasm and the degradation through a system that is lysosomal dependent [76]. Another set of studies using
mice knock-out for HDAC4 and HDAC5 indicates that during osteoclast differentiation, PTH signaling favors MEF2C-dependent transcription by inducing HDAC4 poly-ubiquitylation and degradation via the E3 ubiquitin ligase SMURF2 [77]. Whether these differences reflect a
specific cellular context still needs to be investigated. Class IIa HDACs can also be SUMOylated [11].
In particular, HDAC4 becomes SUMOylated on lysine 559 by the SUMO E3-ligase RanBP2 on the nucleopore complex, during nuclear import [11]. The
SUMOylation increases the interaction of HDAC4 with HDAC3 and therefore its repressive capability [11].
Also HDAC5 and HDAC9, but not HDAC7, are SUMOylated respectively on lysines 605 and 549 [11].
The lack of HDAC7 SUMOylation is probably due to the absence of the glutamine rich region [78].
Table 2. miRNAs targeting class IIa histone deacetylase.
miRNA Target Biological process regulated Pathway/feed-back Ref.
miR-1 HDAC4 Myogenesis, chondrocyte hypertrophy, some
cancers
Induced by MEF2; induced by myod after mtor activation
[29–31,33– 34,54–56]
miR-9 HDAC4 Neurogenesis Induced by MEF2C [32]
miR-2861 HDAC4, HDAC5 Chondrocyte hypertrophy, productivity of recombinant CHO cell lines
[51,52]
miR-365 HDAC4 Chondrocyte hypertrophy [35]
miR-29a HDAC4 Myogenesis [37]
miR-206 HDAC4 Myogenesis, muscle hypertrophy, amyotrophic
lateral sclerosis, gastric cancer
Represses by HDAC4 in KEAP-1 deficient lung cancer cells
[37–41]
miR-22 HDAC4 Neurodegeneration, myogenesis, cardiac
hypertrophy, hepatocellular carcinoma
[47–49,57]
miR-483-5p HDAC4 Neurogenesis [50]
miR-140 HDAC4 Chemosensitivity [58]
miR-9* HDAC4, HDAC5 Waldenström macroglobulinemia
pathogenesis
[59]
miR-200a HDAC4 HCC proliferation and migration Repressed by HDAC4 [62]
miR-125a-5p HDAC4 Breast cancer aggressiveness [63]
miR-155 HDAC4 B-cells proliferation [64]
miR-140-5p HDAC7 Metastatization of tongue squamous cell
carcinoma
[65]
miR-34 HDAC7 Breast cancer refractoriness to treatment [66]
miR-188 HDAC9 Osteogenesis [53]
Figure 3. Schematic representation of class IIa histone deacetylases amino-terminal region highlighting the
principal domains and the ‘canonical’ and ‘not canonical’ 14-3-3 phosphorylation sites see also Table 3. As
prototype of class IIa we selected HDAC4.
NH2- NLS2 GSK3β SUMO559 665 HDAC domain 632 467 298 246 201 202 289 CASP3 PKA 302 14-3-3 independent sites 14-3-3 dependent sites MEF2 NLS1
Class IIa HDACs are not merely targets of SUMO E3-ligases, but several evidences indicate that they could promote the SUMOylation of some partners. They are involved in the activation of Ubc9, the SUMO E2-ligase [79]. In this manner, class IIa HDACs
promote the SUMOylation of MEF2s [79], of
promy-elocytic leukemia protein [80] and of the nuclear
recep-tors LXRα/NR1H3 and LXRβ/NR1H2 [81]. In the
last example, SUMOylation stimulates the binding of the nuclear receptors to STAT1 and thus the inhibition of an inflammatory response [81].
In & out from the nucleus
The control of the nuclear/cytoplasm shuttling is a widespread strategy to influence class IIa HDACs activities. This regulation provides evident advantages in terms of reaction time. A redistribution of class IIa between the two compartments is a quick response that allows an immediate and reversible adaptation of the cells to the new environmental conditions [82–84]. Once
dephosphorylated and nuclear, class IIa HDACs may associate with HDAC3 and N-CoR/SMRT, forming the enzymatically active multiprotein complex capable of driving epigenetic changes [85].
Since class IIa HDACs exert their function mainly in the nucleus, a cytoplasmic accumulation is gener-ally considered as a negative regulation [23,86]. For
example, the nuclear localization prevails in undiffer-entiated cells, whereas differundiffer-entiated cells prevalently accumulate class IIa in the cytosol [87].
By controlling the availability of the NLS to bind importin-α and of the NES to bind CRM1, cells mod-ulate class IIa HDACs protein localization. Phosphor-ylation is the PTM used to modulate these bindings and hence, to control class IIa subcellular localization (Figure 3&Table 3). CaMKII was initially discovered as the kinase that elicits the nuclear export [86]. Today
we know that various kinases are involved in such task. The supervisors of the opposite action (dephosphoryla-tion and nuclear import) were discovered much later,
associated to the activity of the phosphatases PP1 and PP2A [84,88–89].
The control is operated through the phosphoryla-tion of at least three (four in HDAC7) serine residues conserved among HDAC4, 5, 7 and 9 (HDAC4: Ser 246, 467, 632; HDAC5: Ser 259, 497, 661; HDAC7: Ser 155, 181, 321, 446; HDAC9: Ser 220, 451, 611); these phosphorylation events facilitate the binding by dimers of 14-3-3 chaperones [90,91].
Binding of 14-3-3 proteins could either mask the NLS, thus preventing the nuclear import [82,83], or
unmask the NES and thus promoting the direct inter-action with CRM1 [89], or both conditions (although
direct evidences of an interaction between HDAC4 and CRM1 are not available). It is still an open ques-tion whether the interacques-tion between 14-3-3 proteins and class IIa HDACs occurs in the nucleus, in the cyto-plasm or in both compartments. The interaction with 14-3-3 proteins would induce a conformational change in the deacetylases, which would make them able to expose the carboxy-terminal fragment containing the NES to CRM1 [86]. A work by Nishino et al. proposed
that instead, the 14-3-3 proteins act primarily by slow-ing down the nuclear import of the deacetylases, in particular of HDAC4 [83].
In cardiomyocytes, HDAC4 is phosphorylated by the splicing isoforms, b and c, of CaMKIIδ and this finding demonstrates that the phosphorylation of HDAC4 could occur both in the nucleus (isoform b) and in the cytoplasm (isoform c). In the first case the export is favored whereas, in the second, the nuclear import is prevented [92].
Different class IIa HDACs members evidence dif-ferent propensity to accumulate into the nucleus. For example, in transformed fibroblasts HDAC5 is almost nuclear, while HDAC4 is largely cyto-plasmic or present in both compartments [93,94].
In this review the discussion is focused on three families of kinases.
Calcium-regulated kinases
The kinases responsive to calcium are historically associated to HDACs nuclear export. CaMKI and IV phosphorylate all family members and show preference for residues 246 and 467 (in HDAC4 and the cor-responding aa in other deacetylases), while CaMKII preferentially phosphorylates serines 467 and 632 of HDAC4 [87,95]. CaMKII phosphorylates and exports
directly only HDAC4, because only HDAC4 has a CaMKII-specific docking site, centered on Arg601 [95].
However, since HDAC4 can form heterodimers with HDAC5 and 9, but not with HDAC7 [96], the
asso-ciation between HDAC4 and HDAC5/9 renders such proteins responsive to CaMKII. In particular HDAC4 interacts strongly with HDAC5 through the glutamine-rich region [96]. The lack of this region in HDAC7
explains its inability to interact with HDAC4 [78,96].
The calcium-mediated export of class IIa HDACs is involved in the regulation of many physiological processes, such as myogenesis, hypertrophy and neu-ronal survival [97–99]. In general, the prosurvival effect
associated to HDAC4 nuclear export depends on the activation of a MEF2-transcriptional response [98].
In cardiomyocytes, the pro-hypertrophic stimuli can be transduced by cAMP via the exchange protein directly activated by cAMP sensor, which activates PLC, H-Ras and CAMKII. This pathway culminates in the cytoplasmic accumulation of HDAC4 [100].
Exchange protein directly activated by cAMP is a gua-nosine nucleotide exchange factor for the Rap small GTPase. In particular PLC, and the subsequent
sig-naling cascade of the inositol 1,3,5 triphosphate causes a release of calcium in the cytoplasm that determines the export of HDAC4 via CaMKII, followed by the activation of MEF2-dependant transcription [100].
For further and more detailed reviews on calcium-mediated class IIa regulation see [5,90,91]. PKD
PKD, a serine/threonine kinase activated by PKC, was associated to class IIa HDACs export during lymphocyte maturation and thymic selection [101,102].
B-lymphocyte activation, following BCR (B cell recep-tor) engagement is accompanied by the stimulation of PKD1 and PKD3, which in turn phosphorylate HDAC5 and HDAC7 on classical 14-3-3 sites. As a consequence, HDAC5 and HDAC7 accumulate in the cytoplasm and chromatin relaxation can occur [102],
thus switching on the MEF2 transcriptional pro-gram [103]. Since the two kinases are redundant, in
order to abrogate the export of HDAC5, a double knock-out of PDK1 and PDK3 is required.
PKD1 is also a regulator of T-lymphocyte thymic selection [104]. In ‘resting’ double positive CD4+CD8+
thymocytes, nuclear HDAC7 maintains switched off the MEF2 genetic program and in particular the transcription of the proapoptotic nuclear receptor Nur77/NR4A1, the main responsible for the negative selection. In response to T-cell receptor engagement, PKD1 becomes active and phosphorylates HDAC7, which is exported into the cytoplasm. This export deter-mines the activation of MEF2s and the derepression of NR4A1 that promotes cell death [101,104].
PKD is also an important inducer of cardiac hyper-trophy via phosphorylation and export of HDAC5 and
Table 3. Main kinases involved in class IIa histone deacetylases phosphorylation.
Kinase HDAC4 HDAC5 HDAC7 HDAC9
CaMKI, IV 246, 467 259, 497 155, 181, 321 220, 451 CaMKII 467, 632 – – – PKD1 246, 467, 632 259, 497, 661 155, 181, 321, 446 220, 451, 611 (?) C-TAK1, EMK 246 259 155 220 (?) AMPK 246, 467 (?) 259, 497 ? ? SIK1 246, 467 259, 497 155, 321 (?) 220, 451 (?) SIK2 246, 467, 632 259, 497, 661 155, 321, 446 220, 451, 611 (?) PKA 265, 266, 740 278, 279 – 243 DIRK1B 266 276 240 GSK3β 298, 302 AURKB 265 278 242 CDK5 – 279 – –
the relative derepression of MEF2 [105]. Mice with a
cardiac-specific deletion of PKD1 show diminished hypertrophy in response to pressure overload or chronic adrenergic and angiotensin II signaling. Several selec-tive inhibitors of PKD are now under clinical stud-ies for the treatment of malignant cardiac hypertro-phy [105]. PKD1 seems to be an inducer of hypertrophy
also in VSMCs. Here, treatment with the hypertrophic inducer angiotensin II stimulates the phosphorylation of HDAC5 via PKD1 [106]. Similarly, angiotensin II
through PKD1 triggers HDAC4 (serines 246/632), HDAC5 (serines 259/498) and HDAC7 (serine 155) phosphorylation in intestinal epithelium [107].
Finally, exogenous expression of PKD1 in type II skeletal muscle fibers promotes the phosphorylation and the nuclear export of HDAC4 and HDAC5, the subsequent activation of MEF2 TFs and the fibers-switch from fast/glycolytic into red oxidative (slow-twitch type I) [108], in accordance to the phenotype
observed in transgenic MEF2C-VP16 mice [74]. LKB1-ARK family
The tumor suppressor kinase LKB1 regulates different downstream kinases, which belong to the ARK fam-ily (AMP-related kinases) and includes AMP-activated protein kinase (AMPK), microtubule affinity regulat-ing kinases (MARKs), SNF-related kinases (SNRKs), NUAKs (NUAK family, SNF1-like kinases), BR serine/threonine kinases and salt inducible kinases (SIKs) [109].
Early studies reported that MARK kinases phos-phorylate class IIa HDACs constitutively on a con-served residue (S159 in HDAC7, S246 in HDAC4, S259 in HDAC5). This base-line phosphorylation facilitates the subsequent signal-dependent phos-phorylation by other kinases of the remaining resi-dues required for 14-3-3 binding [110]. MARK/PAR-1
kinases are involved in the determination of polarity. During early embryogenesis they control gastrula polarization in Drosophila [111] and the first
asymmet-ric division in Caenorhabditis elegans [112]. Scenarios
where the nuclear or cytoplasmic activities of class IIa HDACs are still unexplored.
The AMPK
The AMPK is activated under conditions of metabolic stress and ATP depletion [109]. Some evidences
corre-late AMPK activity to HDAC4 and HDAC5 cytosolic accumulation [113,114]. In skeletal muscle, the stress
induced by physical exercise is sufficient to trigger the export of HDAC4 and 5 and this relocalization cor-relates with the activation of AMPK and CaMKII [115].
In myotubes the AMPK agonist AICAR (5-amino-imidazole-4-carboxamide-1-beta-D-ribofuranoside)
triggers HDAC5 phosphorylation at S259 and S498 and association with 14-3-3 isoforms. HDAC5 phos-phorylation determines its detachment from the GLUT4 promoter and the concomitant increase in GLUT4 expression [116]. This metabolic regulation can
be supervised also by other kinases such as PKDs [117]. The SIK subfamily
The SIK-subfamily is composed of three isoforms: SIK1, SIK2 and SIK3, conserved from C. elegans to humans. SIK1 expression is highly induced in adrenal glands of high-salt diet-fed rats, whereas SIK2 is highly expressed in adipose tissue. By contrast, SIK3 is ubiq-uitously expressed [118]. Several studies have reported
correlations between SIKs activities, class IIa HDACs relocalization and transcriptional changes [119–121].
The SIK-class IIa HDAC axis is a critical compo-nent of the adaptation to fasting in liver [22]. After
feeding, the release of insulin stimulates in liver and skeletal muscle, the synthesis of glycogen and in adi-pocytes the storage of energy reserves. These responses involve the engagement of Akt and culminate in the phosphorylation-mediated inactivation of PGC-1α and FOXO1/3 [122]. The FOXO TFs are also negatively
regulated by acetylation, which promotes their export into the cytoplasm. Here, the SIK-class IIa HDACs axis becomes protagonist.
In mouse hepatocytes, in response to insulin SIK2 mediates phosphorylation, 14-3-3 binding and cyto-solic accumulation of HDAC4. Accordingly, the fast-ing hormone glucagon, through the PKA-mediated inhibition of SIK2 favors dephosphorylation and nuclear accumulation of HDAC4 [123].
Inhibition of LKB1/AR kinases is followed by the nuclear relocalization of class IIa HDACs, a key-event in order to promote the activation of the gluconeo-genesis in the liver. Nuclear class IIa HDACs associ-ated with HDAC3 in order to deacetylate and activate FOXO1/3. Then, FOXO1/3 stimulate the transcription of key enzymes for the gluconeogenesis [22].
In the adipose tissue, modulation of SIK2 influ-ences HDAC4 phosphorylation through a multipro-tein complex, which comprises also CREB-regulated transcription co-activator 2 and 3, as well as PP2A. This complex is under the supervision of PKA and is involved in the regulation of GLUT4 transcription and glucose uptake [124].
Recently, HDAC4 has been described as an immune-metabolic sensor. In particular under over-nutrition, leptin reduces inflammatory gene expression via HDAC4 nuclear accumulation [125].
proin-flammatory genes in M2 macrophages [125]. Because
obesity promotes macrophage infiltration in white adipose tissues and liver, inflammation and subse-quent insulin resistance, the negative effect of HDAC4 on NF-κB suggests for a protective role against obe-sity [125]. In agreement, HDAC4 variants have been
associated with both body mass index and waist cir-cumference [125] and its expression is downregulated in
the fat from obese subjects [126].
The involvement of the HDACs-SIKs axis in the control of energy supply and metabolism seems to be conserved during evolution. In Drosophila HDAC4 nuclear accumulation in the fat body cells is vised by the LKB1-SIK3 signaling, under the super-vision of different dietary conditions. SIK3 controls lipid metabolism by limiting HDAC4-mediated FOXO activation and ATGL/Bmm transcription (adi-pose triglyceride lipase). In the control of lipid metab-olism HDAC4 behaves as a lipolytic factor [127].
SIKs can monitor class IIa HDACs activities also independently from metabolism. In muscle cells, SIK1 phosphorylates class IIa HDACs thus promoting their export into the cytoplasm [119,128]. In this
con-text, SIK1 could integrate cAMP signaling with the myogenic program [129]. In C. elegans the expression
of chemoreceptors gene in certain chemosensory neu-rons is under the regulation of a SIK member (KIN-29), which controls the localization of the class IIa HDAC counterpart (HDA-4). This control releases the repressive influence of HDA-4 on MEF2-target genes. In the circuit participate also the phosphatase Calcineurin, which instead promotes HDA-4 nuclear accumulation and chemoreceptors repression [130].
Finally, in a detailed study performed in HEK293 cells, Walkinshaw et al. evaluated 13 kinases of the LKB1 family (MARK1, MARK2, MARK3/C-TAK1, NUAK1/ARK5, NUAK2/SNARK, SNRK, NIM1) for the regulation of class IIa HDACs subcel-lular localization [94]. They demonstrated that only
the ectopic expression of SIK2 or SIK3 but not of SIK1 causes a dramatic cytoplasmic relocalization of HDAC5 and HDAC9 and, at a lesser extent, of HDAC4 and HDAC7. For the cytoplasmic relocaliza-tion of class IIa HDACs the catalytic activity of SIK2 is required, while the catalytic activity of SIK3 is dis-pensable. Moreover, while SIK2 promotes the nuclear export through the phosphorylation of 14-3-3 consen-sus sites, SIK3 is effective also on the Ser/Ala mutants in the 14-3-3 binding sites of HDAC4. This result proves that the SIK3-mediated export is both kinase activity and classical 14-3-3 binding sites indepen-dent [94]. Finally, while SIK2 causes the derepression
of MEF2 and stimulates myogenesis in C2C12 cells, SIK3 is incompetent toward MEF2 activation [96].
Whether these differences reflect cell lineage specific features or others conditions is currently unknown.
The large number of studies on the LKB1-SIKs-class IIa HDACs axis underlines the extreme flexibil-ity of the class IIa HDACs, and in particular of the nuclear/cytoplasmic regulation. By a simple operation (nuclear exit) it is possible to reset the transcriptional landscape of cells by both inducing MEF2-target genes and repressing FOXO-target genes.
Phosphatases & nuclear import
More than 15 years ago it was demonstrated that Calyculin A, an inhibitor of the phosphatases PP1 and PP2A, promotes the nuclear export of HDAC4 and reduces its interaction with importin-α [82].
Several years later the contribution of the PP2A complex was proved. PP2A is able to bind the amino-terminal portion of class IIa HDACs, in corre-spondence of the NLS1 and to dephosphorylate these regulators [84,88,89].
In HDAC4 two residues have been proposed as tar-gets of PP2A: serine 246 and 298. Serine 298 is also regulated by GSK3β and constitutes a signal for poly-ubiquitylation and degradation [75]. The
PP2A-medi-ated dephosphorylation may therefore also protect HDAC4 from the UPS-mediated nuclear degradation.
The PTH-related peptide suppresses MEF2 and RUNX2 transcriptional activities and chondrocyte hypertrophy, via PP2A, which dephosphorylates HDAC4 at serine 246 [89]. PP2A is sufficient to
trig-ger the import of HDAC4 and inhibition of PP2A, in U2OS cells, causes the cytoplasmic relocalization of the deacetylase [89].
Ataxia telangiectasia is a complex syndrome char-acterized by neurodegeneration and epigenetic repro-gramming and caused by mutations of the ATM kinase [131]. Since ATM phosphorylates and
inhib-its PP2A, ataxia telangiectasia is characterized by HDAC4 nuclear accumulation in neurons. Here, HDAC4 represses MEF2 and CREB thus inducing heterochromatinization and neurodegeneration [132].
The myosin phosphatase complex, consisting of PP1β and MYPT1, is necessary to repress NUR77. This complex is able to dephosphorylate HDAC7, thus stimulating its nuclear relocalization [94,133]. In
smooth muscles, the myosin phosphatase dephos-phorylates the myosin light chain, thus inducing muscle relaxation and it is inactivated following the phosphorylation of MYPT1 on threonine 696 [134].
Kinases regulated by the GTPase RhoA are able to phosphorylate and inhibit myosin phosphatase on this residue [134] and they are also responsible for the
nuclear export of HDAC5 [134]. It is therefore possible
resulting in the hyperphosphorylation and export of HDAC5 [134].
PP1α is another phosphatase capable of mediat-ing HDAC4 nuclear import. Its action can overcome the antagonist activating effect of calcineurin on MEF2 [135].
The regulation of class IIa HDACs phosphoryla-tion is a complex issue, not limited to 14-3-3 binding sites but involving additional residues. In the case of HDAC5, at least 17 phosphorylation sites have been characterized, 13 of which do not encompass the consensus for 14-3-3 proteins [136]. In particular, the
phosphorylation of serine 279 is essential to induce the nuclear import of the protein. This residue is con-served among all class IIa HDACs, with the excep-tion of HDAC7 [136]. Curiously, this residue was
pre-viously characterized as an Mirk/DirkB target, but in this case its phosphorylation causes the nuclear export of class IIa HDACs [137]. Additional kinases
respon-sible for HDAC5 Ser279 phosphorylation have been identified in PKA and CDK5 [138,139]. PKA retains
HDAC5 in the nucleus by interfering with 14-3-3 binding, thus causing suppression of MEF2-depen-dant cardiac fetal gene expression and cardiomyocyte hypertrophy [138]. On the opposite, CDK5 promotes
HDAC5 nuclear export in neurons. In this con-text, cocaine administration activates PP2A, which dephosphorylates Ser279 and determines the nuclear import of HDAC5 [139]. In the nucleus HDAC5 can
repress genes regulated by cocaine [139].
The opposite influence on HDAC5 subcellular localization by the phosphate group on serine 279 is puzzling. Additional substrates of these kinases could explain the paradox. It is evident that further studies are necessary to clarify this point.
14-3-3 independent regulation of subcellular localization
There are some indications about a 14-3-3-indepen-dent control of class IIa nuclear/cytoplasmic shut-tling. An example concerns the import regulated by TRX1 (thioredoxin 1) in cardiomyocytes [140]. TRX1
is able to recruit HDAC4 in the nucleus and to inhibit the activity of some pro-hypertrophic factors such as MEF2 and NFAT [140]. This adjustment of HDAC4
‘shuttling’ is tissue-specific and mediated through the control of the redox state of two cysteines [140].
Cardiac hypertrophy is characterized by an increase in intracellular reactive oxygen species (ROS) [90].
Under oxidizing conditions, a disulfide bridge between the cysteines 667 and 669 is formed [140].
Cysteine 667 lies in the binding site for the ‘structural’ zinc ion [141,142]. In a reducing environment, cysteines
667 and 669 and the zinc ion bound to its binding
site leads to a protein folding that brings the struc-tural zinc-binding domain in contact with the NES. In this manner the CRM1 binding site is masked and the nuclear export is blocked. In the presence of oxi-dants, cysteines 667 and 669 are oxidized, the zinc is no longer coordinated, the NES is exposed to CRM1 and the protein is exported into the cytoplasm [140].
TRX1 is able to attenuate cardiac hypertrophy in part by restoring the cytoplasmic reducing environ-ment. Furthermore, after the binding to TBP-2, TRX1 reduces DnaJB5 (Hsp40), which in this state can interact with HDAC4. Next the complex TRX1-TBP-DnaJB5 reduces the disulfide bridge 667–669 of HDAC4. This intervention is sufficient for deter-mining the nuclear accumulation of HDAC4, in spite of its phosphorylation status [140,143]. Similarly to
HDAC4, also HDAC5 has been recently described as a redox-sensor in adult heart [144].
As discussed above, the AMPc through PKA owns different options to influence class IIa HDACs subcel-lular localization. An additional opportunity consists in the PKA-promoted (clearly indirect) dephosphory-lation of serines 265/266 in HDAC4, independently from the above-described action on SIK2. These residues are conserved in HDAC5 (278/279) and in HDAC9 (242/243) and lie within the NLS [94]. Their
dephosphorylation favors class IIa nuclear accumula-tion and the subsequent repression of MEF2D and myogenesis [138]. However, since PKA
phosphory-lates also MEF2D [145], it is difficult to
discrimi-nate between the repressive activity of PKA due to the direct phosphorylation of MEF2s or the nuclear import of a class IIa HDACs.
During the cell cycle, HDAC4, HDAC5 and HDAC9, but not HDAC7 can be phosphorylated by Aurora B kinase, respectively on Ser265, Ser278 and Ser242. These phosphorylations allow the relocaliza-tion of the deacetylases at the mitotic midzone during late anaphase, and in the midbody during cytokine-sis [146]. This phosphorylation-dependent
relocaliza-tion abolishes the interacrelocaliza-tion with the NCoR com-plex, thus limiting part of class IIa deacetylase activity [146].
Overall, the regulation of class IIa HDACs func-tions during the cell cycle is largely unexplored, although it could provide important hints on the rela-tionships between this gene family and the control of proliferation.
Conclusion
role, additional opportunities are emerging such as the control of transcription and translation. In sum-mary, cells dispose of different operating layers to influence class IIa HDACs activities. This complexity reflects the astonishing number of biological processes under the supervision of this gene family. It seems that each control is sculptured under the needs of specific conditions.
Future perspective
Although studies on class IIa HDACs are intense, there are several important questions, which still need to be answered, for example, cytoplasmic versus nuclear functions, redundancy, compensatory regula-tive circuits, transcriptional repression and activation, histones versus transcription factors modifications and many others issues. Investigation on class IIa HDACs will certainly proceed in the next future and
addi-tional pieces to this intricate puzzle will be step by step added.
Financial & competing interests disclosure
Research activities in the laboratory of C Brancolini are sup-ported by AIRC (IG-10437) and MIUR Progetto PRIN (Progetto 2010W4J4RM_002). The authors have no other relevant affili-ations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Executive summary
• Class IIa histone deacetylases (HDACs) are exposed to multilayered levels of controls, reflecting the multiple biological responses under their supervision.
Transcriptional control
• Few data are available about the transcriptional machinery responsible for class IIa HDACs expression. • Interrogation of ENCODE database indicates that several transcription factors (TFs) including oncogenes and
cell cycle regulators bind the proximal promoter of class IIa HDACs.
• HDAC4 and HDAC7 proximal promoters are exposed to intense TFs and epigenetic modifiers binding.
Translational control
• Different microRNAs can influence class IIa HDACs translation.
• In some cases, class IIa HDACs are part of feedback circuits controlling the transcription of their own regulative microRNA.
• Further studies are necessary to clarify the effective contribution of class IIa HDACs to the biological role of the specific microRNAs.
Proteolytic control
• Class IIa HDACs levels can be regulated by the ubiquitin-proteasome system and further studies are necessary to define the E3 ligases involved.
• Specific proteolytic cleavages can also influence class IIa HDACs activities in a member specific fashion. • Although the involvement of caspases during apoptosis is well known, additional proteases operating in
different circumstances may exist.
Phosphorylation, 14-3-3 binding & subcellular localization
• The most common and widespread mechanism to influence class IIa HDACs activities.
• Several environmental conditions and signaling pathways use this post-translational modification for influencing class IIa HDACs.
• A fast response that allows an immediate and reversible adaptation of the cells to the new environmental conditions.
14-3-3 independent regulation of subcellular localization
• Less characterized, nevertheless experimental evidences indicate that 14-3-3 independent control of class IIa HDACs does exist.
• Up to now the best characterized mechanism involves the redox control of a pair of cysteine residues lied in the deacetylase domain of HDAC4.
Future perspective
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1 Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834–840 (2009).
2 Yang X-J, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9(3), 206–218 (2008).
3 Clocchiatti A, Di Giorgio E, Demarchi F, Brancolini C. Beside the MEF2 axis: unconventional functions of HDAC4. Cell. Signal. 25(1), 269–276 (2013).
4 Clocchiatti A, Florean C, Brancolini C. Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis. J. Cell. Mol. Med. 15(9), 1833–1846 (2011).
5 Parra M. Class IIa HDACs – new insights into their functions in physiology and pathology. FEBS J. 282(9), 1736–44 (2015).
6 Thierry-Mieg D, Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol. 7(Suppl. 1), S12.1–S14.1 (2006).
7 Zhou B, Margariti A, Zeng L et al. Splicing of histone deacetylase 7 modulates smooth muscle cell proliferation and neointima formation through nuclear β-catenin translocation. Arterioscler. Thromb. Vasc. Biol. 31(11), 2676–2684 (2011).
8 Margariti A, Xiao Q, Zampetaki A et al. Splicing of HDAC7 modulates the SRF-myocardin complex during stem-cell differentiation towards smooth muscle cells. J. Cell Sci. 122(Pt 4), 460–470 (2009).
9 Petrie K, Guidez F, Howell L et al. The histone deacetylase 9 gene encodes multiple protein isoforms. J. Biol. Chem. 278(18), 16059–16072 (2003).
10 Zhang CL, McKinsey TA, Olson EN. The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis. Proc. Natl Acad. Sci. USA 98(13), 7354–7359 (2001).
11 Kirsh O, Seeler JS, Pichler A et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21(11), 2682–2691 (2002).
12 Liu F, Pore N, Kim M et al. Regulation of histone deacetylase 4 expression by the SP family of transcription factors. Mol. Biol. Cell. 17(2), 585–597 (2006).
13 Sleiman SF, Langley BC, Basso M et al. Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J. Neurosci. 31(18), 6858–6870 (2011).
14 Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer Res. 35(2), 645–51 (2015).
15 Zhang L, Jin M, Margariti A et al. Sp1-dependent activation of HDAC7 is required for platelet-derived growth factor-BB-induced smooth muscle cell differentiation from stem cells. J. Biol. Chem. 285(49), 38463–72 (2010).
16 Zhou B, Margariti A, Zeng L et al. Splicing of histone deacetylase 7 modulates smooth muscle cell proliferation and
neointima formation through nuclear -catenin translocation. Arterioscler. Thromb. Vasc. Biol. 31(11), 2676–2684 (2011). 17 Tang H, Macpherson P, Marvin M et al. A histone
deacetylase 4/myogenin positive feedback loop coordinates denervation-dependent gene induction and suppression. Mol. Biol. Cell. 20(4), 1120–1131 (2009).
18 Vega RB, Matsuda K, Oh J et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555–566 (2004).
19 Barneda-Zahonero B, Román-González L, Collazo O et al. HDAC7 Is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet. 9(5), e1003503 (2013).
20 Addis RC, Prasad MK, Yochem RL et al. OCT3/4 regulates transcription of histone deacetylase 4 (Hdac4) in mouse embryonic stem cells. J. Cell. Biochem. 111, 391–401 (2010).
21 Haberland M, Arnold MA, McAnally J, Phan D, Kim Y, Olson EN. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell. Biol. 27(2), 518–525 (2007).
22 Mihaylova MM, Vasquez DS, Ravnskjaer K et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607–621 (2011).
23 Clocchiatti A, Di Giorgio E, Ingrao S, Meyer-Almes F-J, Tripodo C, Brancolini C. Class IIa HDACs repressive activities on MEF2-depedent transcription are associated with poor prognosis of ER+ breast tumors. FASEB J. 27, 942–954 (2013).
24 Clocchiatti A, Di Giorgio E, Viviani G et al. The MEF2– HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro. J. Cell Sci. 128(21), 3961–3976 (2015).
25 Rosenbloom KR, Dreszer TR, Long JC et al. ENCODE whole-genome data in the UCSC genome browser: update 2012. Nucleic Acids Res. 40, D912–D917 (2012).
26 Di Giorgio E, Clocchiatti A, Piccinin S et al. MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation. Mol. Cell. Biol. 33, 4473–91 (2013).
27 Zhu J, Shimizu E, Zhang X, Partridge NC, Qin L. EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and Osterix. J. Cell. Biochem. 112(7), 1749–1760 (2011).
28 Vella P, Barozzi I, Cuomo A, Bonaldi T, Pasini D. Yin Yang 1 extends the Myc-related transcription factors network in embryonic stem cells. Nucleic Acids Res. 40(8), 3403–3418 (2012).
29 Chen J-F, Mandel EM, Thomson JM et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228–233 (2006).
31 Ikeda S, He A, Kong SW et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated
calmodulin and Mef2a genes. Mol. Cell. Biol. 29, 2193–2204 (2009).
32 Davila JL, Goff LA, Ricupero CL et al. A positive feedback mechanism that regulates expression of miR-9 during neurogenesis. PLoS ONE 9(4), e94348 (2014).
33 Sun Y, Ge Y, Drnevich J, Zhao Y, Band M, Chen J. Mammalian target of rapamycin regulates miRNA-1 and follistatin in skeletal myogenesis. J. Cell Biol. 189, 1157–1169 (2010).
34 Li P, Wei X, Guan Y, Chen Q, Zhao T, Sun C, Wei L. MicroRNA-1 regulates chondrocyte phenotype by repressing histone deacetylase 4 during growth plate development. FASEB J. 28( 9), 3930–3941 (2014).
35 Guan Y-J, Yang X, Wei L, Chen Q. MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4. FASEB J. 25, 4457–4466 (2011).
36 Li Z, Hassan MQ, Jafferji M et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J. Biol. Chem. 284(23), 15676–15684 (2009).
37 Winbanks CE, Wang B, Beyer C et al. TGF-b regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J. Biol. Chem. 286, 13805–13814 (2011).
38 Williams AH, Valdez G, Moresi V et al. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326(5959), 1549–1554 (2009).
39 Valsecchi V, Boido M, De Amicis E, Piras A, Vercelli A. Expression of muscle-specific MiRNA 206 in the progression of disease in a murine SMA model. PLoS ONE 10(6), e0128560 (2015).
40 Ren J, Huang HJ, Gong Y et al. MicroRNA-206 suppresses gastric cancer cell growth and metastasis. Cell Biosci. 5(4), 26 (2014).
41 Singh A, Happel C, Manna SK et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J. Clin. Invest. 123(7), 2921–2934 (2013).
42 Ago T, Liu T, Zhai P et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978–993 (2008).
43 Gagan J, Dey BK, Layer R, Yan Z, Dutta A. Notch3 and Mef2c proteins are mutually antagonistic via Mkp1 protein and miR-1/206 microRNAs in differentiating myoblasts. J. Biol. Chem. 287(48), 40360–40370 (2012).
44 Gruber AJ, Zavolan M. Modulation of epigenetic regulators and cell fate decisions by miRNAs. Epigenomics 5(6), 671–83 (2013).
45 Mielcarek M, Landles C, Weiss A et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 11(11), e1001717 (2013).
46 Mielcarek M, Toczek M, Smeets CJ et al. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet. 11(3), e1005021 (2015).
47 Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos M de F, Luthi-Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific huntington’s disease-related mechanisms. PLoS ONE 8(1), e54222 (2013).
48 Huang ZP, Chen J, Seok HY et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ. Res. 112(9), 1234–1243 (2013).
49 Lu W, You R, Yuan X et al. The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell-dependent emphysema. Nat. Immunol. 16(11), 1185–1194 (2015).
50 Han K, Gennarino VA, Lee Y et al. Human-specific regulation of MeCP2 levels in fetal brains by microRNA miR-483–5p. Genes Dev. 27(5), 485–490 (2013).
51 Li H, Xie H, Liu W et al. A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. J. Clin. Invest. 119(12), 3666–3677 (2009).
52 Fischer S, Paul AJ, Wagner A et al. miR-2861 as novel HDAC5 inhibitor in CHO cells enhances productivity while maintaining product quality. Biotechnol Bioeng. 112(10), 2142–2153 (2015).
53 Li CJ, Cheng P, Liang MK et al. MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J. Clin. Invest. 125(4), 1509–1522 (2015).
54 Nasser MW, Datta J, Nuovo G et al. Down-regulation of micro-RNA-1 (miR-1) in lung cancer: suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J. Biol. Chem. 283, 33394–33405 (2008).
55 Datta J, Kutay H, Nasser MW et al. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res. 68, 5049–5058 (2008).
56 Duan Z, Choy E, Nielsen GP et al. Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J. Orthop. Res. 6, 746–752 (2010).
57 Zhang J, Yang Y, Yang T et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br. J. Cancer 103, 1215–1220 (2010).
58 Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46), 4065–4074 (2009).
59 Roccaro AM, Sacco A, Jia X et al. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 116(9), 1506–1514 (2010).
60 Wilson AJ, Byun D-S, Nasser S et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol. Biol. Cell 19, 4062–4075 (2008).
61 Mottet D, Pirotte S, Lamour V et al. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28, 243–256 (2009).
